SKIP000382 |
SKIP ID |
SKIP000382 |
Organism(En) |
- |
Organism(Ja) |
- |
Cell Type(En) |
- |
Cell Type(Ja) |
- |
Cell Tissue(En) |
- |
Cell Tissue(Ja) |
- |
Cell Origin |
Diseased |
Cell Name 1(En) |
HPS0244 |
Cell Name 1(Ja) |
HPS0244 |
Cell Name 2(En) |
- |
Cell Name 2(Ja) |
- |
Disease Name 1(Ja) |
X連鎖αサラセミア·精神遅滞(ATR-X)症候群 |
ICD Code 1 |
D560 |
Disease Name 1(En) |
X-Linked alpha-Thalassemia, Mental Retardation Syndrome (ATR-X syndrome) |
OMIM1 |
301040 |
Disease Name 2(Ja) |
- |
ICD Code 2 |
- |
Disease Name 2(En) |
- |
OMIM 2 |
- |
Disease Name 3(Ja) |
- |
ICD Code 3 |
- |
Disease Name 3(En) |
- |
OMIM 3 |
- |
Age |
- |
Age Range |
-- |
Sex |
-- |
Race(En) |
- |
Race(Ja) |
- |
Genetic Diagnosis |
No |
Not Detected |
No |
Description(En) |
Disease specific iPS cell line derived from a patient : X-Linked alpha-Thalassemia, Mental Retardation Syndrome (ATR-X syndrome) |
Description(Ja) |
疾患特異的iPS細胞株。X連鎖alphaサラセミア·精神遅滞(ATR-X)症候群患者由来。 |
Cell Morphology |
human ES-like |
Grade |
Research Grade |
Vector |
Sendai virus |
Transgene |
SeV18+HS-OCT3/4/TSdeltaF, SeV18+HS-SOX2/TSdeltaF, SeV18+HS-KLF4/TSdeltaF, SeV18(HNL)c-MYCQC/TSdeltaF |
Adhesiveness |
- |
Feeder |
Yes |
Feeder Cell |
MEF (X-rays:5000R or MMC) 3-5x10^(5) cells/60mm dish |
Medium |
DMEM/HamF12(2mM L-Glutamine)+20%KSR+0.1mM NEAA+0.1mM 2-Mercaptoethanol+5ng/ml human bFGF |
Genome Editing |
- |
CO2 |
- |
Mycoplasma |
- |
Detection of Contaminants Mycoplasma |
- |
Pluripotent Markers |
- |
Pluripotent Markers Assay |
- |
in vitro Differentiation |
- |
in vitro Differentiation Assay |
- |
in vivo Differentiation |
- |
in vivo Differentiation Assay |
- |
Other 1 Assay |
- |
Other 1 Assay Method |
- |
Other 2 Assay |
- |
Other 2 Assay Method |
- |
Other 3 Assay |
- |
Other 3 Assay Method |
- |
Karyotype |
- |
Karyotype Assay |
- |
Remaining Vector Detection |
- |
Remaining Vector Detection Assay |
- |
STR |
- |
HLA |
- |
Stem Cell Transcriptome analysis |
- |
Stem Cell Transcriptome analysis Assay |
- |
Author Name(En) |
Apply to RIKEN |
Author Name(Ja) |
理研に問い合わせ |
Author Organization(En) |
Apply to RIKEN |
Author Organization(Ja) |
理研に問い合わせ |
Author Contact Email |
- |
PI Organization(En) |
Apply to RIKEN |
PI Organization(Ja) |
理研に問い合わせ |
PI Name(En) |
Apply to RIKEN |
PI Name(Ja) |
理研に問い合わせ |
PI Contact Email |
- |
Availability |
Available |
Provider Organization(En) |
RIKEN BioResource Center -CELL BANK- |
Provider Organization(Ja) |
理化学研究所 バイオリソースセンター 細胞材料開発室 |
Provider Email |
cellips[at]brc[dot]riken[dot]jp |
Provider URL |
http://cell.brc.riken.jp/ |
Ethical Statement(En) |
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. Contact Us : cellips@brc.riken.jp |
Ethical Statement(Ja) |
寄託者の承諾等の特殊な手続きが必要。先ずは、理研細胞バンクにお問い合わせください(cellips@brc.riken.jp)。 |
Terms of Use(En) |
1)The guideline must be observed when using SeV-iPS cells. 2)In relation to the for-profit organizations, please access to the following URL and consult 'iPS Academia Japan, Inc.' (http://ips-cell.net/e/index.php) prior to the utilization of iPS cells. 3)The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the APPROVER. 4)This cell line should be used as a collaboration work with the depositor for two years after (December, 2015) disclosure of this cell line. |
Terms of Use(Ja) |
1) ディナベック株式会社とBRCとの「センダイウイルスベクタートランスファーライセンス学術研究向け覚書」 を確認すること。2) 非営利機関以外の利用者は事前にiPSアカデミアジャパン株式会社(http://ips-cell.net/j/index.php)から確認書を得ること。3) 寄託者から承諾を得ること。4) 公開から2年間 (2015年12月まで) は共同研究とすること。 |
PubMed ID |
- |
DOI |
- |
Title |
- |
Authors |
- |
Journal |
- |
Year |
- |
Volume |
- |
Issue |
- |
Pages |
- |
URL |
- |
Free input |
- |
Note |
- |